Ipilimumab in combination with nivolumab for the treatment of renal cell carcinoma

Yazar: Gao, Xin, McDermott, David F.
Yayımlandı Expert Opin Biol Ther (2018)

Progress in Kidney Cancer Outcomes Through Collaboration, Innovation, and Discovery

Yazar: McDermott, David F., Carducci, Michael
Yayımlandı J Clin Oncol (2018)

PD-1 as a potential target in cancer therapy

Yazar: McDermott, David F, Atkins, Michael B
Baskı/Yayın Bilgisi 2013

VEGF and PD-1 pathway inhibitors in renal cell carcinoma

Yazar: Mantia, Charlene M., McDermott, David F.
Yayımlandı Cancer (2019)

Management of metastatic renal cell carcinoma in patients with poor prognosis

Yazar: Bullock, Andrea, McDermott, David F, Atkins, Michael B
Baskı/Yayın Bilgisi 2010

Enhancing Antitumor Immunity with Antiangiogenic Therapy: A Clinical Model in Renal Cell Carcinoma?

Yazar: Gao, Xin, McDermott, David F., Michaelson, M. Dror
Yayımlandı Oncologist (2019)

The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma

Yazar: Mahoney, Kathleen M., Freeman, Gordon J., McDermott, David F.
Yayımlandı Clin Ther (2015)

Combining Immune Checkpoint and VEGFR Inhibition in Favorable-risk and Elderly Patients with Metastatic Renal Cell Carcinoma

Yazar: Varkaris, Andreas, Xu, Wenxin, Davis, Roger B., Healy, Brian, McDermott, David F.
Yayımlandı Clin Genitourin Cancer (2019)

Refining indications for contemporary surgical treatment of renal cell carcinoma metastatic to the pancreas

Yazar: Demirjian, Aram N, Vollmer, Charles M, McDermott, David F, Mullen, John T, Atkins, Michael B, Callery, Mark P
Baskı/Yayın Bilgisi 2009

FDG-PET as a predictive biomarker for therapy with everolimus in metastatic renal cell cancer

Yazar: Chen, James L, Appelbaum, Daniel E, Kocherginsky, Masha, Cowey, Charles L, Kimryn Rathmell, Wendy, McDermott, David F, Stadler, Walter M
Baskı/Yayın Bilgisi 2013

High dose interleukin-2 registry, PROCLAIM™; higher center-specific IL-2 dose density correlates with higher response rates

Yazar: Wong, Michael K, Daniels, Gregory A, Kaufman, Howard L, McDermott, David F, Morse, Michael A, Aung, Sandra, Lowder, James N
Baskı/Yayın Bilgisi 2013

Implementation of an Interleukin-2 National Registry: an opportunity to improve cancer outcomes

Yazar: Wong, Michael K, Kaufman, Howard L, Daniels, Gregory A, McDermott, David F, Aung, Sandra, Lowder, James N, Morse, Michael A
Baskı/Yayın Bilgisi 2014

The Use of Registries to Improve Cancer Treatment: A National Database for Patients Treated with Interleukin-2 (IL-2)

Yazar: Kaufman, Howard L., Wong, Michael K., Daniels, Gregory A., McDermott, David F., Aung, Sandra, Lowder, James N., Morse, Michael A.
Yayımlandı J Pers Med (2014)

Ipilmumab and cranial radiation in metastatic melanoma patients: a case series and review

Yazar: Schoenfeld, Jonathan D., Mahadevan, Anand, Floyd, Scott R., Dyer, Michael A., Catalano, Paul J., Alexander, Brian M., McDermott, David F., Kaplan, Irving D.
Yayımlandı J Immunother Cancer (2015)

Phase Ib dose-finding study of axitinib plus pembrolizumab in treatment-naïve patients with advanced renal cell carcinoma

Yazar: Atkins, Michael B, Gupta, Shilpa, Choueiri, Toni K, McDermott, David F, Puzanov, Igor, Tarazi, Jamal, Keefe, Stephen, Rosbrook, Brad, Chakrabarti, Debasis, Plimack, Elizabeth R
Yayımlandı J Immunother Cancer (2015)

BEST: A Randomized Phase II Study of Vascular Endothelial Growth Factor, RAF Kinase, and Mammalian Target of Rapamycin Combination Targeted Therapy With Bevacizumab, Sorafenib, and...

Yazar: Flaherty, Keith T., Manola, Judith B., Pins, Michael, McDermott, David F., Atkins, Michael B., Dutcher, Janice J., George, Daniel J., Margolin, Kim A., DiPaola, Robert S.
Yayımlandı J Clin Oncol (2015)

Overall survival of metastatic melanoma patients treated with HD IL-2 followed by immune checkpoint blockade of the CTLA-4 or the PD-1 pathways: analysis of data on the current use...

Yazar: Wong, Michael KK, Morse, Michael A, McDermott, David F, Clark, Joseph I, Kaufman, Howard L, Daniels, Gregory A, Perritt, Jessica C, Hua, Hong, Aung, Sandra
Yayımlandı J Immunother Cancer (2015)

Durability of responses in patients with metastatic renal cell carcinoma treated with high dose interleukin-2 (HD IL-2)

Yazar: Clark, Joseph I, Morse, Michael A, Wong, Michael KK, McDermott, David F, Kaufman, Howard L, Daniels, Gregory A, Perritt, Jessica C, Hua, Hong, Aung, Sandra
Yayımlandı J Immunother Cancer (2015)

Sargramostim plus Ipilimumab vs Ipilimumab Alone for Treatment of Metastatic Melanoma: A Randomized Clinical Trial

Yazar: Hodi, F. Stephen, Lee, Sandra, McDermott, David F., Rao, Uma N., Butterfield, Lisa H., Tarhini, Ahmad A., Leming, Philip, Puzanov, Igor, Shin, Donghoon, Kirkwood, John M.
Yayımlandı JAMA (2014)

A Phase I Trial of Bortezomib and Sorafenib in Advanced Malignant Melanoma

Yazar: Sullivan, Ryan J., Ibrahim, Nageatte, Lawrence, Donald P., Aldridge, Julie, Giobbie-Hurder, Anita, Hodi, F. Stephen, Flaherty, Keith T., Conley, Christine, Mier, James W., Atkins, Michael B., McDermott, David F.
Yayımlandı Oncologist (2015)